DrugPatentWatch Database Preview

Covis Pharma Bv Company Profile

« Back to Dashboard

What is the competitive landscape for COVIS PHARMA BV, and what generic alternatives to COVIS PHARMA BV drugs are available?

COVIS PHARMA BV has nine approved drugs.

There are two US patents protecting COVIS PHARMA BV drugs.

There are twenty-eight patent family members on COVIS PHARMA BV drugs in nineteen countries and five supplementary protection certificates in two countries.

Summary for Covis Pharma Bv

International Patents:	28
US Patents:	2
Tradenames:	9
Ingredients:	7
NDAs:	9

Drugs and US Patents for Covis Pharma Bv

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Covis Pharma Bv	RILUTEK	riluzole	TABLET;ORAL	020599-001	Dec 12, 1995	AB	RX	Yes	Yes
Covis Pharma Bv	ZANAFLEX	tizanidine hydrochloride	TABLET;ORAL	020397-002	Feb 4, 2000		DISCN	Yes	No
Covis Pharma Bv	LANOXIN PEDIATRIC	digoxin	INJECTABLE;INJECTION	009330-004	Approved Prior to Jan 1, 1982		RX	Yes	Yes
Covis Pharma Bv	ALTOPREV	lovastatin	TABLET, EXTENDED RELEASE;ORAL	021316-002	Jun 26, 2002		RX	Yes	No	6,080,778
Covis Pharma Bv	BETAPACE	sotalol hydrochloride	TABLET;ORAL	019865-001	Oct 30, 1992	AB1	RX	Yes	No
Covis Pharma Bv	PRILOSEC	omeprazole magnesium	FOR SUSPENSION, DELAYED RELEASE;ORAL	022056-002	Mar 20, 2008		RX	Yes	Yes	6,428,810		Y

Expired US Patents for Covis Pharma Bv

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Covis Pharma Bv	SULAR	nisoldipine	TABLET, EXTENDED RELEASE;ORAL	020356-003	Feb 2, 1995	4,703,038
Covis Pharma Bv	SULAR	nisoldipine	TABLET, EXTENDED RELEASE;ORAL	020356-001	Feb 2, 1995	4,892,741
Covis Pharma Bv	SULAR	nisoldipine	TABLET, EXTENDED RELEASE;ORAL	020356-006	Jan 2, 2008	5,422,123
Covis Pharma Bv	ALTOPREV	lovastatin	TABLET, EXTENDED RELEASE;ORAL	021316-002	Jun 26, 2002	6,080,778
Covis Pharma Bv	SULAR	nisoldipine	TABLET, EXTENDED RELEASE;ORAL	020356-007	Jan 2, 2008	5,422,123
Covis Pharma Bv	ALTOPREV	lovastatin	TABLET, EXTENDED RELEASE;ORAL	021316-003	Jun 26, 2002	6,485,748

Paragraph IV (Patent) Challenges for COVIS PHARMA BV drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Capsules	2 mg, 4 mg and 6 mg		2007-08-10
	Extended-release Tablets	25.5 mg and 34 mg		2008-11-28
	Extended-release Tablets	8.5 mg and 17 mg		2009-03-02
	Extended-release Tablets	20 mg and 30 mg		2007-11-07
	Extended-release Tablets	40 mg		2007-06-11

International Patents for Covis Pharma Bv Drugs

Country	Document Number	Estimated Expiration
New Zealand	510993
World Intellectual Property Organization (WIPO)	0027366
Portugal	1124539
Australia	1434600
Japan	2010047616
Australia	759257

Supplementary Protection Certificates for Covis Pharma Bv Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
11/016	Ireland		PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE MODIFIED-RELEASE TABLETS; NAT REGISTRATION NO/DATE: PA0970/060/001 20101221; FIRST REGISTRATION NO/DATE: PL17901/0263-0001 20101105
C/GB11/013	United Kingdom		PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
C/GB11/015	United Kingdom		PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
C/GB01/006	United Kingdom		PRODUCT NAME: ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE; REGISTERED: SE 15945 20000310; SE 15946 20000310; UK PL 17901/0068-0069 20000727
12/048	Ireland		PRODUCT NAME: A COMBINATION PRODUCT COMPRISING ASPIRIN AND ESOMEPRAZOLE MAGNESIUM TRIHYDRATE; NAT REGISTRATION NO/DATE: PA 970/063/001 20120831; FIRST REGISTRATION NO/DATE: 5402359; 5402367 5402375 20110812

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Covidien
• Covis Pharma Bv